NCT02080780View on ClinicalTrials.gov

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions
DRUG

Clarithromycin XL

Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg

DRUG

2% Diltiazem

2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)

Trial Locations (1)

07652

TKL Research, Paramus

All Listed Sponsors
collaborator

TKL Research, Inc.

INDUSTRY

lead

Ventrus Biosciences, Inc

INDUSTRY

NCT02080780 - Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects | Biotech Hunter | Biotech Hunter